Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Binilon
- Development stage
- Phase 4
- Lead developer
- Bini Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Binilon** is an oral fixed-dose analgesic formulation marketed by Bini Laboratories containing **caffeine 30 mg and paracetamol 500 mg** per tablet. It is used for symptomatic relief of headache and other mild-to-moderate pain states, with paracetamol providing analgesic and antipyretic activity and caffeine acting as an analgesic adjuvant. The product is a marketed generic pharmaceutical formulation rather than a distinct investigational molecule.
- Brand names
- Binilon
- Other names
- acetaminophen + caffeinecaffeine + paracetamolparacetamol + caffeine
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Binilon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Binilon.